Ingen Technologies Inc. - IGNT

[bob11]

Ingen Engages New SEC Auditing Firm


Company Legal and Accounting Team Focuses on SEC Filings
YUCAIPA, Calif., Oct 30, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has hired Anton & Chia, LLP as the new auditing firm after dismissing Child, Van Wagoner and Bradshaw on Wednesday of this week.
The Irvine-California based Anton & Chia's team of professionals consist of certified public accountants that are able to assist Ingen with the 10-KSB ending May 31, 2009 and future filings. This firm has over 40 years of experience working with small to middle market companies and understands Ingen's needs. Anton & Chia are licensed CPAs in the following states: California, Colorado, Florida and New York and have a professional staff that are fluent in speaking and writing Mandarin, Cantonese, Italian, and Spanish. As specialists in the realm of public company accounting and reporting, the professionals of Anton & Chia, LLP go to great lengths to ensure the accuracy and timeliness of required financial reporting, compliance and transaction-related issues for our public clients. With the immediate needs of Ingen, Anton & Chia will assist the company in preparing for and meeting obligations in the increasingly complex regulatory environment of public companies in order to comply with rules of the U.S. Securities and Exchange Commission (SEC) and obligations promulgated by the Sarbanes-Oxley Act of 2002.

"We found a firm that can meet our filing schedule. Our legal and accounting team is working very close with the SEC and the new auditors to complete and file the 10-KSB ending May 31, 2009 and subsequent 10-Q's to bring current our filing obligations," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Anton & Chia, LLP

Ingen Technologies,Inc. - Home

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

[mickymoose99]

Pinnacle Digest: Looking For Shareholder Opinions On Ingen Technologies' Latest News

Nov 02, 2009 (M2 PRESSWIRE via COMTEX) -- Pinnacle Digest | Your Investment Growth Resource | Pinnacle Digest is a performance-driven online financial magazine and social network with a proven track record. After Friday's news from Ingen Technologies, Inc. (Pink Sheets:IGNT) announcing that the company has hired Anton & Chia, LLP as the new auditing firm after dismissing Child, Van Wagoner and Bradshaw on Wednesday of this week, our team is inviting all shareholders to their exclusive investor controlled forum. Our staff and members have requested that all Ingen shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.
Join The Ingen Investor Discussion Here: Ingen Technologies Inc | Pinnacle Digest

Join PinnacleDigest.com to

Find out if Ingen makes it as a Pinnacle Featured Company,

Chat with other shareholders invested in Ingen,

Explain to our investor community what differentiates this company,

Connect with investors and professionals in the equity markets,

Meet the thousands of investors who have already become members of the Pinnacle community.

PinnacleDigest.com is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.

PinnacleDigest.com has no vested interest in the company mentioned herein. The company mentioned in this release has not compensated PinnacleDigest.com in any form to disseminate this release.

This source of information is from an unbiased perspective. If you wish to become a member of Pinnacle Digest | Your Investment Growth Resource | Pinnacle Digest you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.

All material herein was prepared by Pinnacledigest.com (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by Pinnacledigest.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Pinnacledigest.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Pinnacledigest.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Pinnacledigest.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Pinnacledigest.com undertakes no obligation to update such statements.

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.




(C)1994-2009 M2 COMMUNICATIONS
-0-

[bob11]

Ingen CEO Live Radio Interview Tomorrow With The Money Channel


CEO Discusses Projections for 2010 of $10M in Sales

YUCAIPA, Calif., Nov 2, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss conservative projections for 2010 tomorrow, Tuesday November 3, 2009, at 11:24AM on The Money Channel's American Scene Radio with host Steve Crowley.
A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.

The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.

With proper marketing, advertising, branding, distribution and direct sales; Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December 2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.

With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.

"With the new auditors in place, and near completion of the required SEC filings, the management is focused on increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Welcome

U.S. Senior Population Projections by Age (2010-2050) - Bar Charts - Swivel

COPD Statistics

Ingen Technologies,Inc. - Home

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire, GlobeNewswire - Press Release Distribution - EDGAR Filings - Video News Releases

SOURCE: Ingen Technologies, Inc.


By Staff

CONTACT: CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
Ingen Technologies,Inc. - Home

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
-0-

INDUSTRY KEYWORD: Healthcare & Medical Services
SUBJECT CODE: MEDICAL
Calendar of Events

[chuck44l]

YUCAIPA, Calif., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss conservative projections for 2010 tomorrow, Tuesday November 3, 2009, at 11:24AM on The Money Channel's American Scene Radio with host Steve Crowley.


A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.



The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.



With proper marketing, advertising, branding, distribution and direct sales; Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December 2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.



With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.



"With the new auditors in place, and near completion of the required SEC filings, the management is focused on increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Welcome



U.S. Senior Population Projections by Age (2010-2050) - Bar Charts - Swivel



http://www.copd-international.com/li...statistics.htm



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.


Contact:
Ingen Technologies, Inc.Jeff Morgan909-790-7180www.info@ingen-tech.com

[bob11]

Stock looks good- and the news is hot- let's go!!!! Need that price appreciation-let's make it happen, captain!!

[mickymoose99]

IGNT
Starting to heat up +16%
RSI Line is @ 42.72 curving up looking good
volume is moving should go over the 10 day avg of 56 million as of now its at 55 million
bids are building .0028 as of now
staring to heat up,

[mickymoose99]

IGNT
congrates to all on IGNT
+ 36%
RSI Line 49.21 and still rising looks good
volume way over the 10 day avg

[chuck44l]

A very nice move today + 40% on almost 90 mil shares traded im watching this one for a break of .0034 on the bid side Support is .0031 and .003 Resistance is the 20 day MA line of .0034 the 50 day MA line of .0037 followed by .0038 .0042 .005 and a possible test of .007

[Stock_Analyzer]

We put this on our nightly stock alerts last week and for Monday morning and so far it has not disappointed us. If we can break .0037 the 50 MA line we could see a big spike after that....keep IGNT on radar imo

[mickymoose99]

IGNT
Yesterdays open 0.0029
Close 0.0033
+ 32%
RSI Line 48.03 and rising
MacD even
Slope curving up
charts look possitive
im looking for IGNT to have another good day